Accutane Mass Tort Alert
MASS TORT AMERICA
CLIENT AGGREGATION SERVICES
MASS TORT ALERT
For client aggregation assistance, contact (210) 635-0468 or info@masstortamerica.com.
Ongoing Mass Tort Action:
Accutane® (isotretinoin) severe nodular acne treatment
Potential Defendant(s)
- Primary: Hoffmann-La Roche, Inc.
- Primary Defendant Financial Data: Revenues: 2009 $49.1B, 2008 $49.5B
- Secondary: Prescribing Physicians, Testing Laboratories, and other entities in the distribution chain. Financial Condition Varies, Mostly Insured.
Potential Plaintiffs
- Individuals prescribed Accutane®.
Potential Plaintiff Numerosity
- FDA approved Accutane® in 1982. Accutane® is taken by approximately 500,000 Americans each year.
Potential Plaintiff Claims
- Wrongful Death, Permanent Disability, Life-Threatening Permanent Injury, Medical Malpractice.
Potential Cause of Action
Accutane® can cause severe, life-threatening birth defects of the baby’s ears, eyes,
face, skull, heart, and brain. Accutane® has also been linked to suicidal ideation and
Aggravating Circumstance: Manufacturer has received FDA Warning for “false or
misleading promotional activities” regarding the safety of Accutane®.
“My investigation demonstrates the insidious nature of how the manufacturer, Roche,
and the FDA continue to mislead Advisory Committees and the American people.”
“The off-label use of Accutane® is so prevalent, that some experts estimate that the
improper use was close to 90% among women.”
“I stated that Roche cannot be trusted and will mislead this Advisory Committee as to
birth defects and adverse events related to Accutane®. As my investigation has shown
by June of 2001, it appears that the FDA could no longer trust Roche officials to tell them
the truth or to provide them with documentation.” — 2007 Statement – Congressman
Bart Stupak – FDA Advisory Committee Hearing on iPLEDGE – August 1, 2007
Client Origination and Aggregation Challenges
Many of the potential plaintiffs injured by prescription use of Accutane® may not be
aware that Accutane® has caused their injury or the death of their loved one. The issue
has received press coverage however , adequate publicity has not occurred to ensure
that all those potentially injured by Accutane are aware of the cause. *Contact us to
discuss our client aggregation services (210) 635-0468 info@masstortamerica.com.
Opportunity
Although this issue is past the initial phase of awareness, there are still a vast number
of potential clients in need of legal assistance. Due to the fact that the use of Accutane
was so wide spread, this issue is likely to remain alive for a lengthy period. *Contact us
to discuss our client aggregation services (210) 635-0468 info@masstortamerica.com.
Client Generation Strategy
Internet search engine domination followed by mass press release. This two-pronged
strategy should be sufficient to aggregate a significant number of plaintiffs. Other forms
of advertising including television could be indicated if justified by the plaintiff volume
acquired in the initial plaintiff aggregation phase. *Contact us to discuss our client
aggregation services (210) 635-0468 info@masstortamerica.com.
Disclaimer
If you are not an Attorney this information is not intended for you. If you need legal help,
please seek the advice of an Attorney. If you need medical help, please seek the advice
of a Medical Doctor. No one should discontinue the use of any medication without
seeking the advice of a Medical Doctor.
The information provided in this alert is not intended to be legal advice. This alert is
provided directly to practicing attorneys and is for the sole use of those attorneys.
Further dissemination of this alert is prohibited. It is assumed that the receiving attorney
has the ability to conduct independent research on the information provided and does
not need to rely solely on the provided information for any purpose.
Accutane® is a registered trademark of F. Hoffmann–La Roche Ltd. Mass Tort America
is not affiliated with Accutane® or F. Hoffmann-La Roche Ltd.
References